GGrantIndex
← Leaderboards

Sami Nimer Malek

University Of Michigan At Ann Arbor

$8,691,121
Attributed
$11,182,307
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200725
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,182,307 · 7

By mechanism

R01$10,850,859 · 6
R21$331,448 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Recurrence

Research focus

RecurrenceCellsMutationGene MutationGenesCohortBaseMolecularDisease RemissionRelapsePathway InteractionsFutureChemotherapyLeukemiaSamplingChronic Lymphocytic LeukemiaProgramsGenomicsBiologicalCessation Of LifeInsightMutantReportingPharmaceutical Preparations

Grant awards (27)

The Biology of Mutant STAT6 in Follicular Lymphoma$713,700
R01 · FY2025 · CA · contact PI
Genes regulating stem and progenitor cell expansion and relapse in Acute Myeloid Leukemia$458,698
R01 · FY2025 · CA · contact PI
The Biology of Mutant STAT6 in Follicular Lymphoma$339,008
R01 · FY2024 · CA · contact PI
The Biology of Mutant STAT6 in Follicular Lymphoma$349,713
R01 · FY2023 · CA · contact PI
Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML$410,483
R01 · FY2022 · CA · contact PI
The Biology of Mutant STAT6 in Follicular Lymphoma$356,850
R01 · FY2022 · CA · contact PI
Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML$418,860
R01 · FY2021 · CA · contact PI
Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML$429,758
R01 · FY2020 · CA · contact PI
The genomic pathogenesis of Follicular Lymphoma$504,983
R01 · FY2019 · CA · contact PI
Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML$416,864
R01 · FY2019 · CA · contact PI
The genomic pathogenesis of Follicular Lymphoma$520,601
R01 · FY2018 · CA · contact PI
Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML$429,758
R01 · FY2018 · CA · contact PI
The genomic pathogenesis of Follicular Lymphoma$541,994
R01 · FY2017 · CA · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$463,347
R01 · FY2017 · CA
The genomic pathogenesis of Follicular Lymphoma$541,994
R01 · FY2016 · CA · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$463,347
R01 · FY2016 · CA
The genomic pathogenesis of Follicular Lymphoma$556,205
R01 · FY2015 · CA · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$463,347
R01 · FY2015 · CA
Targeted Elimination of Cancer Stem Cells for AML Therapy$447,360
R01 · FY2014 · CA
Targeted Elimination of Cancer Stem Cells for AML Therapy$479,195
R01 · FY2013 · CA
Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia$291,182
R01 · FY2013 · CA · contact PI
Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia$308,524
R01 · FY2012 · CA · contact PI
Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia$308,596
R01 · FY2011 · CA · contact PI
Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia$318,211
R01 · FY2010 · CA · contact PI
Genomic Complexity and Clinical Outcome in Chronic Lymphocytic Leukemia$318,281
R01 · FY2009 · CA · contact PI
Genomic Profiling and clinical Outcome in Chronic Lymphocytic Leukemia$149,048
R21 · FY2008 · CA · contact PI
Genomic Profiling and clinical Outcome in Chronic Lymphocytic Leukemia$182,400
R21 · FY2007 · CA · contact PI